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Coronary Artery Disease (CAD)
• CAD is the leading cause of death in the 
Western World for men and women
• CAD is narrowing of the small blood vessels that 
supply blood and oxygen to the heart (coronary 
arteries). 
• Coronary disease usually results from the build-
up of fatty material and lessions called plaque. 
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Atherosclerosis
• Atherosclerosis is an 
intimal disease 
which fatty material 
collects along the 
walls of arteries. 
• stenosis
• As the coronary 
arteries narrow, the 
flow of blood to the 
heart can slow or 
stop.
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Treatment
• For overcome this problem Percutaneous 
Transluminal Coronary Angioplasty (PTCA) was 
introduced in the last period of 70’s and has 
become a common method for treating coronary 
arterial stenosis.
• A balloon is used to open narrowed or blocked 
blood vessels of the heart coronary arteries 
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• PTCA with a balloon has a major limitation 
called restenosis which is the maladaptive 
response of the coronary artery to injury and 
characterized by re-narrowing of the artery after 
the angioplasty. 
• Restenosis can be described currently as 
consisting of two components: first called 
“elastic recoil” and the second component 
called “neointimal hyperplasia”
25.10.2006 GPEN 2006 October 25-27
University of Kansas, Lawrence 7
Stents
• Stent is a small, metal tube that is inserted 
permanently into an artery. 
• Acts as a scaffold, remaining in place 
permanently to help keep the artery open.
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• Restenosis rates in patients who have 
stents implanted are 20–40%.
In-Stent restenosis
Metallic bare stents - Not Enough
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Drug Eluting Stents (DES)
• DES provide both mechanical scaffolding and 
local delivery of a pharmacological agent.
• DES reduced the in-stent restenosis rates
• The need of a stent?   Safety?
• Biodegradable Polymeric Stents
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Aim
• Prednisolone Acetate (PA) – model drug
• Biodegradable Stent Formulations;
PA was incorporated into the film based 
polymeric biodegradable stents to provide 
controlled local release of the drug during the 
mechanical support phase
Also PA containing spray-dried chitosan 
microspheres were incorporated into the 
stents
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Chitosan Microspheres
• 22 Factorial design was used and 8 microsphere 
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Mean Particle Size: 10.41 ± 0.03 µm
In vitro release time: 11 Days 
(100% Cumulative PA Release)
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Surface and Morphology of the Stents
PA incorporated (a) and PA containing chitosan microspheres incorporated (b) 
PLGA (75:25) stents, PA incorporated (c) and PA containing chitosan 
microspheres incorporated (d) PLGA (50:50) stents
(a) (b)
(c) (d)
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The polymer wall thickness was 
136.5 ± 5 µm - PLGA (75:25) stents
109 ± 8 µm - PLGA (50:50) stents
1.5 cm
3 mm
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PLGA (75:25) stents
(a) (b)
PA incorporated (a) PA containing chitosan microspheres 
incorporated (b)
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(a) (b)
PA incorporated (a) PA containing chitosan microspheres 
incorporated (b)
PLGA (50:50) stents
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In Vitro Release
• 2 mL of 0.5% (w/v) sodium lauryl sulfate 
and 0.05% (w/v) sodium azide containing 
Phosphate Buffered Saline (PBS) pH 7.4
• The stents were shaken in Eppendorf 
tubes in a horizontal shaker at 50 rpm, at 
37°C
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Conclusion
• By using biodegradable PLGA (75:25) 
and PLGA (50:50) polymers, 
cardiovascular stents were manufactured 
and characterized.
• Different release profiles were obtained 
with using different polymers. 
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• The released amount of PA from the PLGA 
(50:50) stents (with PA only or PA containing 
microspheres) was always higher
• PA release from the stents which contain 
chitosan microspheres was slower than the 
only PA incorporated ones. Adding 
microspheres instead of drug only, was 
extended the release.
• The stents formulated with PLGA (75:25) 
polymers were considered to be more 
promising.
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